Establishing optimal lymphocyte gates for immunophenotyping by flow cytometry - PubMed (original) (raw)

Review

Establishing optimal lymphocyte gates for immunophenotyping by flow cytometry

M R Loken et al. Cytometry. 1990.

Free article

Abstract

It is possible accurately to distinguish lymphocytes from other leukocyte populations in peripheral blood using the combination of fluorescence associated with CD45/CD14 and forward and orthogonal light scatter. By identifying the cell population of interest based on immunofluorescence, a light scattering window can then be drawn to include all (greater than or equal to 98%) of the lymphocytes. In this manner, maximal recovery of the lymphocytes within a sample can be consistently obtained. The combination of light scattering and immunofluorescence can also be used to define the purity of the gate. The identification of nonlymphocytes within the light scattering gate can then be used to establish an accurate denominator for the percent lymphocytes stained. Once the optimal data acquisition gate has been established and characterized, it is possible to correct subsequent analyses with that particular sample since the reactivity of monoclonal antibodies on monocytes and granulocytes can be accounted for once the nonlymphocytes have been identified as being within the acquisition gate.

PubMed Disclaimer

Similar articles

• Use of CD45 fluorescence and side-scatter characteristics for gating lymphocytes when using the whole blood lysis procedure and flow cytometry.
  Nicholson JK, Hubbard M, Jones BM. Nicholson JK, et al. Cytometry. 1996 Mar 15;26(1):16-21. doi: 10.1002/(SICI)1097-0320(19960315)26:1<16::AID-CYTO3>3.0.CO;2-E. Cytometry. 1996. PMID: 8809476
• Flow cytometric immunophenotyping of lymphocyte subsets in samples that contain a high proportion of non-lymphoid cells.
  Pattanapanyasat K, Kyle DE, Tongtawe P, Yongvanitchit K, Fucharoen S. Pattanapanyasat K, et al. Cytometry. 1994 Dec 15;18(4):199-208. doi: 10.1002/cyto.990180403. Cytometry. 1994. PMID: 7534676
• Increased light scattering resolution facilitates multidimensional flow cytometric analysis.
  Terstappen LW, Mickaels RA, Dost R, Loken MR. Terstappen LW, et al. Cytometry. 1990;11(4):506-12. doi: 10.1002/cyto.990110409. Cytometry. 1990. PMID: 2140548
• Analysis of leukocyte function by flow cytometric techniques.
  Stelzer GT. Stelzer GT. Cytometry Suppl. 1988;3:52-9. doi: 10.1002/cyto.990090812. Cytometry Suppl. 1988. PMID: 3076368 Review. No abstract available.
• Light scatter of isolated cell nuclei as a parameter discriminating the cell-cycle subcompartments.
  Giaretti W, Nüsse M. Giaretti W, et al. Methods Cell Biol. 1994;41:389-400. doi: 10.1016/s0091-679x(08)61730-6. Methods Cell Biol. 1994. PMID: 7861971 Review. No abstract available.

Cited by

• Development of an advanced flow cytometry based high-resolution immunophenotyping method to benchmark early immune response in dairy cows.
  Farschtschi S, Mattes M, Hildebrandt A, Chiang D, Kirchner B, Kliem H, Pfaffl MW. Farschtschi S, et al. Sci Rep. 2021 Nov 24;11(1):22896. doi: 10.1038/s41598-021-02405-w. Sci Rep. 2021. PMID: 34819614 Free PMC article.
• Expression of CD44 in Leukocyte Subpopulations in Patients with Inflammatory Bowel Diseases.
  Franić I, Režić-Mužinić N, Markotić A, Živković PM, Vilović M, Rušić D, Božić J. Franić I, et al. Diagnostics (Basel). 2022 Aug 20;12(8):2014. doi: 10.3390/diagnostics12082014. Diagnostics (Basel). 2022. PMID: 36010364 Free PMC article.
• Modulating the Biologic Activity of Mesenteric Lymph after Traumatic Shock Decreases Systemic Inflammation and End Organ Injury.
  Langness S, Costantini TW, Morishita K, Eliceiri BP, Coimbra R. Langness S, et al. PLoS One. 2016 Dec 15;11(12):e0168322. doi: 10.1371/journal.pone.0168322. eCollection 2016. PLoS One. 2016. PMID: 27977787 Free PMC article.
• Flow cytometric immunophenotyping: principles and pitfalls.
  Othmer M, Zepp F. Othmer M, et al. Eur J Pediatr. 1992 Jun;151(6):398-406. doi: 10.1007/BF01959351. Eur J Pediatr. 1992. PMID: 1628666 Review.
• Activation of the immune system of cancer patients by continuous i.v. recombinant IL-2 (rIL-2) therapy is dependent on dose and schedule of rIL-2.
  Gratama JW, Bruin RJ, Lamers CH, Oosterom R, Braakman E, Stoter G, Bolhuis RL. Gratama JW, et al. Clin Exp Immunol. 1993 May;92(2):185-93. doi: 10.1111/j.1365-2249.1993.tb03378.x. Clin Exp Immunol. 1993. PMID: 8485906 Free PMC article. Clinical Trial.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Wiley

• Other Literature Sources

  • The Lens - Patent Citations Database

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal